These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39359103)

  • 1. Local Sustained Dinutuximab Delivery and Release From Methacrylated Chondroitin Sulfate.
    Mistretta KS; Tiche J; Chiu B; Coburn JM
    J Biomed Mater Res A; 2024 Oct; ():. PubMed ID: 39359103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling methacryloyl substitution of chondroitin sulfate: injectable hydrogels with tunable long-term drug release profiles.
    Ornell KJ; Lozada D; Phan NV; Coburn JM
    J Mater Chem B; 2019 Apr; 7(13):2151-2161. PubMed ID: 32073574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.
    Ornell KJ; Taylor JS; Zeki J; Ikegaki N; Shimada H; Coburn JM; Chiu B
    Cancer Med; 2020 Apr; 9(8):2891-2903. PubMed ID: 32096344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.
    Keyel ME; Reynolds CP
    Biologics; 2019; 13():1-12. PubMed ID: 30613134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
    Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
    Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
    Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
    Mastrangelo S; Rivetti S; Triarico S; Romano A; Attinà G; Maurizi P; Ruggiero A
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review.
    Mohd AB; Mohd OB; Alabdallat YJ; Al Dwairy SY; Ghannam RA; Hanaqtah BM; Albakri KA
    J Res Med Sci; 2023; 28():71. PubMed ID: 38116487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib-Loaded Chondroitin Sulfate Hydrogels as a Novel Drug-Delivery Mechanism for the Treatment of Pancreatic Neuroendocrine Tumors.
    Keutgen XM; Ornell KJ; Vogle A; Lakiza O; Williams J; Miller P; Mistretta KS; Setia N; Weichselbaum RR; Coburn JM
    Ann Surg Oncol; 2021 Dec; 28(13):8532-8543. PubMed ID: 34091777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death.
    Ornell KJ; Chiu B; Coburn JM
    J Biomed Mater Res A; 2021 Aug; 109(8):1393-1405. PubMed ID: 33252182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating a Functional Biomimetic Cartilage Implant Using Hydrogels Based on Methacrylated Chondroitin Sulfate and Hyaluronic Acid.
    Schuiringa GH; Mihajlovic M; van Donkelaar CC; Vermonden T; Ito K
    Gels; 2022 Jul; 8(7):. PubMed ID: 35877542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex coacervation-based loading and tunable release of a cationic protein from monodisperse glycosaminoglycan microgels.
    Schuurmans CCL; Abbadessa A; Bengtson MA; Pletikapic G; Eral HB; Koenderink G; Masereeuw R; Hennink WE; Vermonden T
    Soft Matter; 2018 Aug; 14(30):6327-6341. PubMed ID: 30024582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of chondroitin sulfate concentration and matrix stiffness on chondrogenic differentiation of mesenchymal stem cells.
    Ai C; Liu L; Wong K; Tan XH; Goh JCH
    Biomater Sci; 2023 Jun; 11(13):4557-4573. PubMed ID: 37159255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling methacrylated chitosan hydrogel properties through an experimental design approach: from composition to material properties.
    Bucciarelli A; Selicato N; Coricciati C; Rainer A; Capodilupo AL; Gigli G; Moroni L; Polini A; Gervaso F
    J Mater Chem B; 2024 Oct; 12(40):10221-10240. PubMed ID: 39248047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
    Ploessl C; Pan A; Maples KT; Lowe DK
    Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.